Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 188 Results
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Senior Officer, Drug Spending at Pew Charitable Trusts, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University…
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…
What’s Contributing to Unnecessary Health Spending?
Reducing low-value care—health care that is cost-inefficient and clinically ineffective—remains a front burner issue for health care stakeholders. It hasn’t been easy to root out or measure low-value…
Why the VA Should Proceed with Caution on ICER Collaboration
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute…
An Opportunity to Thoughtfully and Holistically Address Health Care Spending
The Medicare Trustees Annual Report issued last week was a mix of positive news and a stark reminder that we need to find thoughtful solutions to ensure that the Medicare program will remain solvent…
Will Value Assessment Frameworks Promote Health Value and Access for Veterans?
NPC expressed concerns about the partnership between the Institute for Clinical and Economic Review and the U.S. Department of Veterans Affairs Pharmacy Benefits Management Services office to…
NPC Evaluates ICER’s Revised Value Assessment Framework
The Institute for Clinical and Economic Review (ICER) today released its revised value assessment framework, which included a number of changes reflected in NPC's extensive public comments, but NPC…
Asking the Right Questions About Our Health Care System Costs
With health news headlines focused on drug prices, the Senate Committee on Health, Education, Labor and Pensions is holding a hearing today titled, "The Cost of Prescription Drugs: How the Drug…
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.
Why Value Framework Assessments Arrive at Different Conclusions
New peer-reviewed research from the National Pharmaceutical Council (NPC) found inconsistencies in how four value frameworks assessed multiple myeloma treatments.
National Eczema Association Weighs In on Value Frameworks
NPC President Dan Leonard recently sat down for a conversation with Julie Block, President and CEO of the National Eczema Association, to discuss atopic dermatitis (AD) and value assessment…
NPC Outlines Needed Improvements to ICER's Revised Value Assessment Framework
NPC submitted comments to the Institute for Clinical and Economic Review (ICER), offering constructive suggestions on ways to further improve its revised value assessment framework.
Workshop Looks “Under the Hood” of Value Assessment Frameworks
During the Feb. 27 interactive workshop, “Understanding the Strengths and Limitations of Value Assessment Frameworks,” hosted by the National Pharmaceutical Council and PhRMA, health care…
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
Concerns Around Budget Impact Thresholds: Not All Drugs Are The Same
A study published in Value in Health explores the potential impact of using budget thresholds as budget caps (e.g., cannot spend more than a set dollar amount) for individual drugs.
NPC President Dan Leonard Offers Perspectives on Health Reform
In a commentary recently published in The American Journal of Pharmacy Benefits, NPC President Dan Leonard offered 10 key considerations for stakeholders as they navigate health reform discussions.
Comparison of Value Framework Assessments for Multiple Myeloma
In this NPC-funded study conducted by the Lewin Group, four existing value assessment frameworks were compared head to head to understand how each framework would approach the same condition,…
NPC President Dan Leonard Speaks on Value Frameworks at BioNJ
As our health care system shifts from a focus on volume to value, a key question emerges: Who gets to define value? National Pharmaceutical Council (NPC) President Dan Leonard and other health…
How Are Stakeholder Views Incorporated into Value Assessment Frameworks? Watch NPC's New Video
NPC's animated informational video explains how different organizations are trying to consider patient viewpoints through the development of value assessment frameworks.